I am delighted to be able to inform you that we have entered into an option and license agreement with GSK to evaluate iosBio’s thermal stability platform technology.

As you know, the iosBio platform technology enables development of thermally stable vaccines and biopharmaceuticals.

Under the terms of the research collaboration, GSK has the option to take an exclusive license for use in a defined field. We are not able to disclose further terms of the collaboration.

This is the second project we have worked on with GSK and is further technical validation of our technology and a milestone in our commercialization strategy.